AB Science Raises 2.8 Million Euros Through Private Placement
AB Science has announced the raising of a gross amount of 2.8 million euros in a private placement aimed at funding its clinical programs, particularly the AB8939 study.
Capital Increase Through Private Placement
AB Science has carried out a capital increase through a private placement amounting to a gross 2.8 million euros, subscribed by a limited number of investors. This operation was conducted without the need for a prospectus requiring approval from the Financial Markets Authority (AMF). For this placement, 2,477,877 new shares were issued, each accompanied by a warrant. The issue price for a new share with a warrant was set at 1.13 euros, representing a discount of 24.99% compared to the volume-weighted average price of the stock over the three trading days preceding the issue.
Funding Ongoing Activities and Clinical Development
The funds raised in this private placement will enable AB Science to finance its ongoing activities and specifically to continue the clinical development of the AB8939 program. This program includes completing a Phase I clinical study and initiating an expanded study on approximately 15 patients with acute myeloid leukemia. This study, conducted in combination with Venetoclax, aims to produce preliminary evidence of the treatment's efficacy, in support of future clinical trials. Additionally, this fundraising strengthens AB Science's cash reserves, allowing it to cover its financial needs through 2025 and beyond.
Impact on Share Capital
The issuance of new shares results in a slight dilution of the capital. Prior to the operation, the share capital of AB Science consisted of 63,706,916 ordinary shares. After the issuance, this number has increased to 66,184,793 shares, and could rise to 67,671,519 if all the warrants are exercised. The main shareholders, A. Moussy and AMY SAS, see their participation slightly reduced but continue to hold a significant portion of the capital. The newly issued shares will be admitted to trading on Euronext Paris as of October 22, 2025, and will be subject to the same statutory provisions as the existing shares.
